In mice, two doses of psilocybin before chemotherapy kept sensory nerves intact through six cycles
The protection ran through the 5-HT2A receptor and the nerve's mitochondria. The first human trial is scheduled to open in November.
THE DISPATCH
Up to 60 percent of patients on some neurotoxic chemotherapy regimens develop chemotherapy-induced peripheral neuropathy: burning, tingling, or numbness in the hands and feet that can force dose reductions and, for some people, never fully resolves.¹ There is currently no proven way to prevent it. On September 3, 2026, a team at The University of Texas MD Anderson Cancer Center published a study in Science showing that psilocybin, given before chemotherapy, prevented this nerve damage in mice and preserved nerve function in human nerve tissue in the lab.² ³ This is preclinical work, and nothing in it tells us yet what happens in patients. What it does offer is unusually specific biology, and a mechanism that has nothing to do with mood.
In this issue:
→ What the MD Anderson team found, and the cellular pathway they traced it to
→ Why a non-hallucinogenic compound protected the nerves just as well
→ How the first human trial, NeuroGuard, is designed, and what its primary endpoint does and doesn't measure
THE SCIENCE
The study, led by Mario Heles with senior authors Moran Amit and Patrick Dougherty, tested psilocybin in tumor-bearing mice treated with standard chemotherapy agents, including cisplatin and paclitaxel.² ³ Mice received as few as two psilocybin doses before chemotherapy began. Across up to six chemotherapy cycles and roughly eight months of follow-up, treated mice kept normal sensitivity scores on behavioral tests of nerve damage, while untreated mice developed the hypersensitivity typical of neuropathy.² ⁴ Two further results make the finding more useful than a simple "it worked" headline. First, timing mattered: psilocybin given after chemotherapy exposure did not protect the nerves.⁴ This looks like prevention, not repair. Second, the chemotherapy still did its job. Tumors in psilocybin-treated mice shrank as much as tumors in mice that received chemotherapy alone.³ ⁴
The mechanism is where this paper earns its place in Science. Sensory nerve fibers are long, and their distant endings depend on mitochondria being moved down the axon to supply energy. Chemotherapy disrupts that transport, and the nerve endings degenerate first. The MD Anderson team found that psilocybin, acting through the serotonin 2A (5-HT2A) receptor, kept mitochondria moving at normal speed along the axon.¹ ² When they blocked the 5-HT2A receptor with a selective antagonist, volinanserin, the protection disappeared completely.¹ ² The authors traced the effect through a signaling chain that ends at the motor proteins that carry mitochondria along the nerve. Senior co-author Patrick Dougherty put it plainly: psilocybin appears to protect the nerves themselves through energy delivery, rather than only reducing pain signals.³
The human data matter here. The team tested psilocybin on freshly harvested peripheral nerve tissue from 29 surgical patients, as well as on human stem cell-derived sensory neurons and donor dorsal root ganglia. In human nerve tissue exposed to cisplatin, psilocybin kept mitochondrial transport going where cisplatin alone slowed it.¹ ² That is still a lab result, not a clinical one, but it narrows the usual gap between a mouse finding and a human mechanism.
For drug developers, the most interesting result may be a quieter one. TBG, a 5-HT2A agonist that does not produce hallucinogenic effects in animal models, protected nerves about as well as psilocybin did.¹ ² If that holds, the protective effect and the psychedelic experience may be separable. For an oncology patient in the middle of treatment, that difference is not academic. It would shape who can take the drug, where, and under what supervision. It also adds to a pattern this newsletter has followed all year: the same receptor that drives psilocybin's psychological effects also appears to support structural resilience in nerve cells, well outside the brain circuits most people associate with it.
THE STORY
The next step is already registered. NeuroGuard (NCT07227909), a Phase 2 trial sponsored by MD Anderson with the Usona Institute listed as a collaborator, is scheduled to begin enrolling on November 4, 2026, with an estimated 83 participants.⁵ Its design is worth reading closely. Patients will be randomized to one of three arms: two supervised 25 mg psilocybin doses one week apart before the first chemotherapy cycle, then monthly doses before cycles two and three; a second arm of 1 mg subperceptual doses taken every other day during the run-in before each of the first three cycles; or standard care with no study drug.⁵ The trial is open-label, and its registered primary outcome is safety, measured as the incidence of adverse events graded on the National Cancer Institute's standard criteria.⁵ In other words, the first human study is built to answer whether psilocybin can be given safely alongside chemotherapy, not yet whether it prevents neuropathy. Neuropathy outcomes will be informative, but without blinding or a placebo arm they will be early signals. Primary completion is estimated for January 2029.⁵ That timeline is the honest answer to anyone who reads a headline about this study and asks whether they can ask their oncologist for psilocybin now. They can't, and they shouldn't try to source it themselves. The appropriate route is a registered clinical trial.
Rose Hill Life Sciences is a psychedelic research organization, specializing in the production and research of Psilocybe cubensis operating at the intersection of science and therapeutic integration.
ON OUR RADAR
① A Second Pretreatment Finding, This Time for Brain Inflammation
Published August 31, 2026 in BMC Neuroscience, a Virginia Commonwealth University study gave mice a low dose of the psychedelic DOI 24 hours before an immune challenge with bacterial lipopolysaccharide. Pretreated mice showed lower hippocampal levels of the inflammatory markers IL-6 and TNF-alpha, and less of the drop in movement and weight that normally follows.⁶ The authors attribute the effect to 5-HT2A receptor activation. The study used male mice only and a single acute immune trigger, but it points to the same pattern as the MD Anderson paper: protection when the compound is given before the insult.
② A Zurich Mouse Study Finds Psilocybin Strengthened Fear Memory Expression
Published September 22, 2026 in Frontiers in Pharmacology, a University of Zurich study gave psilocybin or ethocybin (3 mg/kg) to mice after aversive conditioning. Both compounds increased freezing behavior at a memory test 72 hours later compared with vehicle (p = 0.041 and p = 0.004).⁷ The authors suggest this could make trauma-related memories more accessible to therapy, while noting that rodent findings may not map onto human responses. It is a useful reminder that these compounds do not simply dampen distress.
③ Redesigning an Old Compound to Drop a Side Effect
In Science Signaling (August 2026), a Virginia Commonwealth University team modified quipazine, a 1960s compound, to keep its 5-HT2A activity while removing activity at the 5-HT3 receptor, which drives nausea and gut slowdown. The new analog, VCU-1012, produced antidepressant-like effects and increased dendritic spine density in mice without the gastrointestinal slowdown.⁸ It still acts on the 5-HT2B receptor, a known cardiac valve risk, so it is a design proof of concept rather than a drug candidate.
YOU ASKED
Q: "If psilocybin protects nerves from chemotherapy, could it help people who already have neuropathy?"
Based on this study, there is no evidence for that yet, and one result points the other way. In the MD Anderson experiments, psilocybin protected nerves when it was given before chemotherapy. When it was given after the nerves had already been exposed, the protection did not appear.⁴ The mechanism fits that pattern: psilocybin kept mitochondria moving into nerve endings that were still intact, rather than rebuilding endings that had already degenerated. Whether a different dosing approach could help established neuropathy is an open question this paper does not test. For now, the evidence supports prevention in animal models, and the NeuroGuard trial is designed around prevention for exactly that reason.
This week's takeaway: in mice, psilocybin given before chemotherapy prevented nerve damage through six cycles by keeping mitochondria moving along sensory axons via the 5-HT2A receptor, without weakening chemotherapy's effect on tumors. The first human trial is designed to establish safety first, with results not expected before 2029.
A question worth sitting with: if a non-hallucinogenic 5-HT2A agonist protects nerves as well as psilocybin does, which of psilocybin's effects are really tied to the psychedelic experience, and which only happen to share its receptor?
Read the study directly: Science: Psilocybin prevents chemotherapy-induced peripheral neuropathy
If you know an oncologist or oncology nurse who hears about neuropathy every week, forward this to them. The mechanism is worth knowing before patients start asking.
— Bryan Smith
PhD, Biologist and Drug Developer
Advancing the development of novel psychedelic-based therapeutics
FOOTNOTES
¹ Compass Pathways. "Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile." July 7, 2026. https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Six-Month-Data-from-Second-Phase-3-Trial-Confirming-Rapid-and-Durable-Profile/default.aspx
² Compass Pathways. "Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression." February 17, 2026. https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-Second-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx
³ Compass Pathways. "Phase 3 COMP006 Data Review" (investor webcast presentation), slide 13. July 7, 2026. https://s204.q4cdn.com/927483861/files/doc_events/2026/Phase-3-006-data-webcast-presentation-7-July-26.pdf
⁴ Compass Pathways. "Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher." 2026. https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-FDA-Granted-NDA-Rolling-Review-Request-and-Awarded-Commissioners-National-Priority-Voucher/default.aspx
⁵ Compass Pathways. "Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights." August 5, 2026. https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Second-Quarter-and-First-Half-2026-Financial-Results-and-Business-Highlights/default.aspx
⁶ Compass Pathways. "Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD." January 7, 2026. https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-FDA-Acceptance-of-IND-Application-for-PTSD-and-Hosts-Webinar-on-PTSD-and-TRD/default.aspx
⁷ Otsuka Pharmaceutical Co., Ltd. "Otsuka Pharmaceutical to Acquire Transcend Therapeutics." March 27, 2026, completed June 15, 2026. https://www.otsuka.co.jp/en/company/newsreleases/2026/20260327_2.html
⁸ MAPS Public Benefit Corporation. "MAPS PBC Announces New American Medical Association CPT III Codes for Psychedelic-Assisted Therapies Take Effect." January 2024. https://www.prnewswire.com/news-releases/maps-pbc-announces-new-american-medical-association-cpt-iii-codes-for-psychedelic-assisted-therapies-take-effect-302024227.html
The Rose Hill Review
Advancing the development of novel psychedelic-based therapeutics.
Get this analysis every week, in your inbox.
Clinical science, veteran data, and honest coverage of psychedelic medicine, every Tuesday.